First City Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.12M Sell
19,427
-18
-0.1% -$1.03K 0.54% 48
2026
Q1
$1.18M Sell
19,445
-170
-0.9% -$9.91K 0.63% 42
2025
Q4
$1.06M Sell
19,615
-1,682
-8% -$80.9K 0.56% 43
2025
Q3
$960K Sell
21,297
-425
-2% -$19.8K 0.52% 46
2025
Q2
$1.01M Buy
21,722
+295
+1% +$14.5K 0.58% 44
2025
Q1
$1.31M Buy
21,427
+263
+1% +$15.3K 0.78% 31
2024
Q4
$1.2M Buy
21,164
+219
+1% +$12.2K 0.64% 40
2024
Q3
$1.08M Buy
20,945
+2,120
+11% +$99.5K 0.56% 43
2024
Q2
$782K Sell
18,825
-7,907
-30% -$354K 0.44% 54
2024
Q1
$1.45M Buy
26,732
+1,171
+5% +$59.7K 0.8% 32
2023
Q4
$1.31M Sell
25,561
-614
-2% -$32.2K 0.76% 35
2023
Q3
$1.52M Sell
26,175
-35
-0.1% -$2.15K 0.95% 30
2023
Q2
$1.68M Sell
26,210
-1,022
-4% -$68.5K 0.99% 26
2023
Q1
$1.82M Sell
27,232
-12
-0% -$846 1.06% 24
2022
Q4
$1.96M Sell
27,244
-1,067
-4% -$80.5K 1.18% 24
2022
Q3
$2.01M Sell
28,311
-25
-0.1% -$1.81K 1.33% 18
2022
Q2
$2.18M Sell
28,336
-125
-0.4% -$9.52K 1.34% 18
2022
Q1
$2.08M Buy
28,461
+544
+2% +$36.5K 1.15% 23
2021
Q4
$1.81M Sell
27,917
-6,080
-18% -$357K 1.02% 27
2021
Q3
$2.01M Sell
33,997
-33
-0.1% -$2.17K 1.13% 26
2021
Q2
$2.28M Sell
34,030
-190
-0.6% -$12.4K 1.25% 23
2021
Q1
$2.21M Buy
34,220
+974
+3% +$60.6K 1.28% 23
2020
Q4
$1.99M Sell
33,246
-28,789
-46% -$1.77M 1.28% 23
2020
Q3
$3.78M Buy
62,035
+29,073
+88% +$1.75M 1.41% 14
2020
Q2
$1.94M Buy
32,962
+904
+3% +$54.1K 1.49% 16
2020
Q1
$1.79M Sell
32,058
-2,646
-8% -$162K 1.75% 15
2019
Q4
$2.23M Sell
34,704
-1,374
-4% -$78.7K 1.53% 16
2019
Q3
$1.83M Sell
36,078
-1,353
-4% -$63.6K 1.34% 19
2019
Q2
$1.7M Sell
37,431
-80
-0.2% -$3.73K 1.24% 25
2019
Q1
$1.79M Sell
37,511
-900
-2% -$44.8K 1.29% 22
2018
Q4
$2M Sell
38,411
-951
-2% -$51.1K 1.56% 13
2018
Q3
$2.44M Sell
39,362
-700
-2% -$41.5K 1.63% 9
2018
Q2
$2.22M Sell
40,062
-145
-0.4% -$7.83K 1.59% 8
2018
Q1
$2.54M Sell
40,207
-370
-0.9% -$23.8K 1.9% 6
2017
Q4
$2.49M Sell
40,577
-150
-0.4% -$9.38K 1.7% 9
2017
Q3
$2.6M Sell
40,727
-800
-2% -$46.7K 1.82% 8
2017
Q2
$2.31M Hold
41,527
1.68% 11
2017
Q1
$2.26M Sell
41,527
-1,854
-4% -$102K 1.66% 11
2016
Q4
$2.54M Buy
43,381
+7
+0% +$383 1.9% 9
2016
Q3
$2.34M Sell
43,374
-660
-1% -$42.4K 1.79% 10
2016
Q2
$3.24M Sell
44,034
-174
-0.4% -$12.3K 2.45% 9
2016
Q1
$2.82M Sell
44,208
-1,540
-3% -$97.1K 1.93% 8
2015
Q4
$3.15M Sell
45,748
-425
-0.9% -$28.1K 2.11% 6
2015
Q3
$2.73M Sell
46,173
-2,101
-4% -$133K 2.01% 7
2015
Q2
$3.21M Buy
48,274
+155
+0.3% +$10.2K 2.23% 7
2015
Q1
$3.1M Sell
48,119
-835
-2% -$52.3K 2.15% 6
2014
Q4
$2.89M Sell
48,954
-1,007
-2% -$56.8K 1.99% 7
2014
Q3
$2.56M Sell
49,961
-272
-0.5% -$13.6K 1.83% 8
2014
Q2
$2.44M Sell
50,233
-672
-1% -$33.1K 1.73% 8
2014
Q1
$2.64M Sell
50,905
-597
-1% -$31.8K 1.89% 6
2013
Q4
$2.74M Sell
51,502
-4,086
-7% -$208K 2.24% 6
2013
Q3
$2.57M Buy
55,588
+3,026
+6% +$133K 2.13% 7
2013
Q2
$2.35M Buy
+52,562
New +$2.28M 2.14% 8

Other funds holding BMY

First City Capital Management's BMY Position: Q2 2026 in Review

First City Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 0.09% in Q2 2026, selling an estimated $1.03K and leaving 19,427 shares worth $1.12M. The position accounts for 0.54% of the portfolio, ranked #48.

First City Capital Management first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.78M in Q3 2020. 888 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • First City Capital Management held 19,427 shares of Bristol-Myers Squibb worth $1.12M as of Q2 2026.
  • First City Capital Management sold 18 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.03K.
  • Bristol-Myers Squibb made up 0.54% of First City Capital Management's portfolio in Q2 2026, its #48 holding.
  • First City Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • First City Capital Management's Bristol-Myers Squibb position peaked at $3.78M in Q3 2020.
  • 888 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on First City Capital Management's 13F filing for Q2 2026, filed 13 Jul 2026.